Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy

5Hold

1Sell

Consensus RatingBuy# Analysts27Avg. Consensus PT$544Upside to Avg. PT+4.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	UBS	Michael Yee	PT Raise	Buy	$585→$615
Sep 11, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$515→$560
Sep 2, 2026	Morgan Stanley	Terence Flynn	Reinstates	Overweight	$665
Aug 5, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$560→$565
Aug 5, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$615→$617
Aug 4, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$525→$550
Aug 4, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$590→$595
Aug 4, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Hold	$436→$442
Jul 13, 2026	UBS	Michael Yee	PT Raise	Buy	$545→$585
Jul 13, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$542→$560
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$543→$570
Jul 7, 2026	Baird	Brian Skorney	PT Raise	Underperform	$330→$350
May 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$607→$615
May 5, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Hold	$437→$436
May 5, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$612→$616
May 5, 2026	Bernstein	William Pickering	PT Cut	Outperform	$577→$572
May 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$541→$543
Apr 30, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Hold	$441→$437
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$596→$612
Mar 18, 2026	Maxim Group	Naz Rahman	Upgrade	Hold→Buy	$575

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $585 to $615.

Benzinga Newsdesk

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.

Vandana Singh

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.

Benzinga Newsdesk

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.

Benzinga Newsdesk

Vertex Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Vertex Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

People Also Watch

People Also Watch

Vertex Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Vertex Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

PROMorgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PROLive On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PROCNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PROTruist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

People Also Watch

People Also Watch

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565